AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Imunon Stock Soars 241.35% on Promising Cancer Treatment Data
Generated by AI AgentAinvest Pre-Market Radar
Friday, May 23, 2025 9:24 am ET1min read
On May 23, 2025, Imunon's stock surged by 241.35% in pre-market trading, marking a significant milestone for the clinical-stage biotechnology company.
Imunon, Inc. is dedicated to advancing a portfolio of treatments that leverage the body's natural mechanisms to combat a variety of human diseases. The company's innovative approach involves the development of non-viral
technology across four distinct modalities. TheraPlas is designed to code proteins and cytokines for the treatment of solid tumors, while PlaCCine focuses on coding viral antigens to elicit a strong immunological response. aims to produce universal cancer vaccines, and IndiPlas is in the discovery phase, concentrating on personalized cancer vaccines.The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy specifically developed for the localized treatment of advanced ovarian cancer. This program has shown promising results, contributing to the recent surge in investor interest and stock performance. The prolonged survival observed in studies of IMNN-001 has further bolstered confidence in the company's innovative approach to cancer treatment.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
ECARX Holdings plunges 8.33% in pre-market trading on investor caution ahead of earnings report and sector volatility
Dec.23 2025
WhiteFiber Surged 9.38% in Pre-Market Trading on Strategic Sector Optimism
Dec.23 2025
Dave & Buster's Entertainment shares plunge 5.70% pre-market on mixed analyst signals and Q4 revenue contraction
Dec.23 2025
BlackSky Technology (BKSY) shares rise 13.61% pre-market as Jefferies initiates coverage with Buy rating and $23 price target
Dec.23 2025
SEALSQ Surges 5.24% in Pre-Market Trading on Investor Confidence and Sector Rotation
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet